AstraZeneca’s Fourth Quarter Earnings Fall Short of Consensus, But Promises Double-Digit Growth in 2024

In the world of pharmaceuticals, AstraZeneca is a well-known name. The company has been making headlines recently with its reported core earnings for the fourth quarter of 2020. While the numbers fell just short of consensus, AstraZeneca remains optimistic about its future growth.

Let’s take a closer look at the details.

Fourth Quarter Earnings

AstraZeneca reported its core earnings for the fourth quarter of 2020, which ended on December 31st. The company’s earnings per share (EPS) came in at $1.38, falling just short of the consensus estimate of $1.39. This slight miss may have disappointed some investors, but AstraZeneca’s overall performance for the quarter was still strong.

The company’s total revenue for the quarter was $7.41 billion, a 10% increase from the same period in 2019. This growth was driven by strong sales of AstraZeneca’s key products, including its cancer drugs and respiratory treatments.

2024 Growth Expect  

Share This Article
Leave a comment